DNLI News and Press, Denali Therapeutics Inc. From 10/26/23

2023-10-26 09:49:41 ET Summary INmune Bio is a phase 2 stage biotech company focusing on Alzheimer's and other diseases with its lead asset, XPro, and its endogenous NK cell activator, INKmune. INmune's XPro has shown promising results in stabilizing Alzheimer's disease and improv...

2023-10-02 05:26:09 ET Summary Denali Therapeutics shows promising early-phase data with DNL310 in Hunter syndrome, alongside robust Q2 financials, including $183.4M net income. Despite a strong cash position and revenue diversification, Denali's stock underperformed the S&P 5...

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer PR Newswire CAMBRIDGE, Mass. , Sept. 11, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda K...

Additional biomarker data up to two years of treatment continue to demonstrate rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers Additional safety data up to two years of treatment continue to demonstrate that ...

Invaio achieves first registration for citrus greening solution featuring Trecise™ technology PR Newswire FDACS approves first registration of Invaio's Trecise™ technology to deliver ArborBiotic™ for the suppression of citrus greening in oranges Citrus...

2023-08-14 05:45:30 ET Summary Coya Therapeutics is developing Treg-enhancing therapeutics to target diseases driven by inflammation, including in the central nervous system, including ALS. Coya Therapeutics' ALS drug could be approved based on pivotal phase 2 results and could po...

2023-08-08 17:16:49 ET Denali Therapeutics press release ( NASDAQ: DNLI ): Q2 EPS of $1.30 may not be comparable to consensus of -$0.63. Revenue of $294.12M (+460.4% Y/Y) beats by $254.61M . For further details see: Denali Therapeutics EPS of $1.30, revenue o...

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal st...

2023-07-23 00:51:26 ET Summary Denali Therapeutics is a promising underdog in the biotech sector, focusing on neurodegenerative diseases, with significant investments in scientific exploration and a robust financial health despite net losses. The company's pipeline includes seven ...

2023-07-17 00:45:27 ET Summary Denali Therapeutics reported Q1 2023 losses of $109.8 million, up from $65.2 million in Q1 2022, with reduced revenue from partnerships with Takeda and Biogen. The company's Phase 1/2 trial for DNL310, a treatment for Hunter syndrome, showed a signif...